Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

被引：1
|
作者：
Vaduganathan, Muthiah
Sattar, Naveed
Fitchett, David H.
Ofstad, Anne Pernille
Brueckmann, Martina
George, Jyothis T.
Verma, Subodh
Mattheus, Michaela
Wanner, Christoph
Inzucchi, Silvio E.
Zinman, Bernard
Butler, Javed
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-30-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
30-OR
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME
    Pellicori, Pierpaolo
    Ofstad, Anne Pernille
    Fitchett, David
    Zeller, Cordula
    Wanner, Christoph
    George, Jyothis
    Zinman, Bernard
    Brueckmann, Martina
    Lindenfeld, JoAnn
    ESC HEART FAILURE, 2020, 7 (06): : 3401 - 3407
  • [22] Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
    Ryden, Lars
    Shahim, Bahira
    Mellbin, Linda
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1279 - 1287
  • [23] Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
    Udell, J.
    Zinman, B.
    Wanner, C.
    Von Eynatten, M.
    George, J. T.
    Zwiener, I.
    Lund, S. S.
    Hantel, S.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2019, 40 : 55 - 55
  • [24] Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
    McGuire, Darren K.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Fitchett, David
    Anker, Stefan D.
    Pocock, Stuart
    Kaspers, Stefan
    George, Jyothis T.
    von Eynatten, Maximilian
    Johansen, Odd Erik
    Jamal, Waheed
    Mattheus, Michaela
    Elsasser, Ulrich
    Hantel, Stefan
    Lund, Soren S.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (12): : 949 - 959
  • [25] Use of loop diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
    Pellicori, P.
    Fitchett, D.
    Kosiborod, M.
    Ofstad, A. P.
    Seman, L.
    Zinman, B.
    Zwiener, I.
    Wanner, C.
    George, J. T.
    Inzucchi, S. E.
    Testani, J.
    Cleland, J. G. F.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S444 - S445
  • [26] EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR DEATH IN SUBGROUPS BYAGE: RESULTS FROM EMPA-REG OUTCOME
    D'Emden, M.
    Fitchett, D.
    Kis, Giljanovic S.
    Woerle, H.
    Zinman, B.
    Inzucchi, S.
    NEPHROLOGY, 2016, 21 : 58 - 58
  • [27] Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG Outcome
    Ridderstrale, Martin
    Toural, Elvira
    Fitchett, David
    Kis, Sanja Giljanovic
    Woerle, Hans J.
    Mattheus, Michaela
    Zinman, Bernard
    Inzucchi, Silvio E.
    DIABETES, 2016, 65 : A289 - A290
  • [28] Reduced progression of kidney disease with empagliflozin: results from EMPA-REG OUTCOME
    Wanner, C.
    Inzucchi, S.
    Lachin, J. M.
    Fitchett, D.
    von Eynatten, M.
    Mattheus, M.
    Johansen, O. E.
    Woerle, H. J.
    Broedl, U. C.
    Zinman, B.
    DIABETIC MEDICINE, 2017, 34 : 80 - 81
  • [29] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Toural, E.
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. -J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S. E.
    DIABETOLOGIA, 2016, 59 : S539 - S540
  • [30] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1192 - 1192
12345